---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-004324"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2025-07-07T23:59:59+00:00"
generated_at: "2026-05-18T09:24:02.438090+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioCryst appoints Babar Ghias as CFO and Head of Corporate Development

## Summary
- Babar Ghias named CFO, effective July 7, 2025; also serves as Principal Accounting Officer.
- Annual base salary of $560,000; target bonus 70% of salary; one-time cash bonus of $160,000.
- Inducement grants: 147,000 RSUs and options to purchase 305,000 shares, vesting over 4 years.
- Ghias joins from AvenCell Therapeutics; previously EVP at Paragon Biosciences and CFO at Marathon Pharmaceuticals.
- CEO Stonehouse cites Ghias' deal-making and operational experience for growth and capital deployment.

## SEC filing metadata
- accession: 0001171843-25-004324
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2025-07-07T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184325004324/0001171843-25-004324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184325004324/f8k_070725.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-004324
- JSON: https://secwatch.observer/filing/0001171843-25-004324.json
- Plain text: https://secwatch.observer/filing/0001171843-25-004324.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.